Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 513,200 shares, a decrease of 21.5% from the March 31st total of 653,800 shares. Based on an average trading volume of 321,500 shares, the short-interest ratio is currently 1.6 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spero Therapeutics stock. Acadian Asset Management LLC raised its stake in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 56.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 272,024 shares of the company’s stock after buying an additional 98,485 shares during the period. Acadian Asset Management LLC owned about 0.52% of Spero Therapeutics worth $327,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Stock Down 1.4 %

Shares of Spero Therapeutics stock traded down $0.02 on Monday, reaching $1.44. The company’s stock had a trading volume of 170,558 shares, compared to its average volume of 290,765. The company has a market capitalization of $77.61 million, a price-to-earnings ratio of 3.43 and a beta of 0.55. Spero Therapeutics has a 52 week low of $0.99 and a 52 week high of $2.00. The firm’s fifty day simple moving average is $1.63 and its two-hundred day simple moving average is $1.42.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Wednesday, March 13th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of ($0.18) by $1.14. The company had revenue of $73.52 million during the quarter, compared to the consensus estimate of $19.40 million. Spero Therapeutics had a return on equity of 38.54% and a net margin of 21.98%. As a group, research analysts predict that Spero Therapeutics will post -0.94 EPS for the current year.

Analysts Set New Price Targets

SPRO has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Spero Therapeutics in a research note on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Thursday, April 4th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.